Maddalena Marconato
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
The challenge of patient recruitment into early phase clinical trials: Is time-effective academic translational research feasible? Lessons from a phase I/II trial in patients with B-cell deficiencies.
Journal: Frontiers in medicine
Published: March 31, 2026
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.
Journal: The Lancet. Haematology
Published: September 18, 2025
Validation of the ELN2024 and Mayo Genetic Risk Models in an External Cohort of 352 Patients With Newly Diagnosed AML Receiving Less-Intensive Therapies.
Journal: American journal of hematology
Published: June 10, 2025
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: August 28, 2023
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study.
Journal: The Journal of infectious diseases
Published: July 20, 2023
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Journal: Nature communications
Published: June 14, 2023
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia.
Journal: Scientific reports
Published: February 07, 2022
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.
Journal: The Journal of clinical investigation
Published: January 06, 2022
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Journal: Nature
Published: August 17, 2021
Last Updated: 09/26/2026